

Amendments to the Claims:

Please cancel claims 1-4, 13 and 21-23, and amend the remaining claims as follows.

Listing of Claims:

1-23. (Canceled).

24. (Currently amended) A method of preventing ~~thrombosis~~ thrombus formation on a ~~liquid-containing~~ liquid-contacting surface of a liquid delivery system, the liquid delivery system being connected to a patient for delivery of a liquid to said patient, the method comprising first contacting said surface with a solution containing a ~~thrombosis-~~ preventing ~~thrombus-~~ preventing amount of an anticoagulant agent other than taurolidine or taurultam, thereafter contacting said surface with a solution containing taurolidine, taurultam or a mixture thereof, and repeating both of the surface contacting steps between delivery of liquids to said patient.

25. (Previously Presented) The method of claim 24 wherein the solution containing taurolidine, taurultam or mixture thereof is contacted with said surface for at least about 1 hour.

26. (Previously Presented) The method of claim 25 wherein said solution containing taurolidine, taurultam or mixture thereof is sealed in said delivery system for a period of at least 12 hours.

27. (Previously Presented) The method of claim 26 wherein said solution containing taurolidine, taurultam or mixture thereof which is sealed in said delivery system, is replaced at least about daily.

28. (Previously Presented) The method of claim 24 wherein the anticoagulant-containing solution is contacted with said surface by injecting the anticoagulant-containing solution

into said liquid delivery system and then removing said anticoagulant-containing solution from said liquid delivery system.

29. (Previously Presented) The method of claim 28 wherein the solution containing taurolidine, taurultam or a mixture thereof is contacted with said surface for at least about 1 hour.

30. (Previously Presented) The method of claim 29 wherein said solution containing taurolidine, taurultam or a mixture thereof is sealed in said delivery system for a period of at least about 12 hours.

31. (Previously Presented) The method of claim 30 wherein the solution containing taurolidine, taurultam or a mixture thereof which is sealed in said delivery system is replaced at least about daily.

32. (Previously Presented) The method of claim 24 wherein said solution containing taurolidine, taurultam or a mixture thereof contains from about 0.5 to about 3% by weight of taurolidine, or from about 1 to about 7.5% by weight of taurultam.

33. (Previously Presented) The method of claim 24 wherein said anticoagulant agent is selected from the group consisting of sodium citrate, aprotinin, hirudin, desirudin, danaparoid, danaparoid-sodium, heparin, pentosan, pentosanpolysulfate-sodium, ticlopidine, clopidogrel, and mixtures thereof.

34. (Previously Presented) The method of claim 33 wherein said anticoagulant agent is present in an amount within a range of from about 0.1-10mg.

35. (New) A method of preventing thrombus formation on a liquid-contacting surface of a liquid delivery system, the liquid delivery system being connected to a patient for delivery of a liquid to said patient, the method comprising first contacting said surface with a

solution containing a thrombus-preventing amount of an anticoagulant agent other than taurolidine or taurultam, thereafter contacting said surface with a solution containing taurolidine, taurultam or a mixture thereof, and further conducting both of the surface contacting steps between subsequent delivery of liquids to said patient.

36. (New) A method of preventing thrombus formation on a liquid-contacting surface of a liquid delivery system, the liquid delivery system being connected to a patient for delivery of a liquid to said patient, the method comprising first contacting said surface with a solution containing a thrombus-preventing amount of an anticoagulant agent other than taurolidine or taurultam, thereafter contacting said surface with a solution containing taurolidine, taurultam or a mixture thereof, and further conducting the surface contacting step with the solution containing taurolidine, taurultam or a mixture thereof between subsequent delivery of liquids to said patient.